Publications by authors named "J Naude"
Objectives: The response to glucagon-like peptide-1 (GLP-1) analogues for weight loss varies significantly. We investigated the anthropometric, demographic and clinical characteristics associated with total body weight loss (TBWL) from subcutaneous GLP-1 analogue therapy in patients with obesity in a real-world setting.
Design: Retrospective cohort analysis.
Phasic variations in dopamine levels are interpreted as a teaching signal reinforcing rewarded behaviors. However, behavior also depends on the motivational, neuromodulatory effect of phasic dopamine. In this study, we reveal a neurodynamical principle that unifies these roles in a recurrent network-based decision architecture embodied through an action-perception loop with the task space, the MAGNet model.
View Article and Find Full Text PDFObjective: Little is known about the effect of a multi-drug weight loss strategy in obesity treatment, particularly combining bupropion/naltrexone and glucagon-like peptide 1 (GLP-1) analogue. The purpose of this study was to evaluate if there are any additive effects of prescribing bupropion/naltrexone on top of GLP-1 analogue as weight loss therapy.
Methods: This was a retrospective cohort study of adult patients with a body mass index (BMI) ≥ 30 kg/m prescribed GLP-1 analogue therapy at an obesity specialist clinic in Vancouver, Canada.
Article Synopsis
- HIV-associated tuberculosis (TB) leads to high mortality rates, especially in severely ill hospitalized patients, prompting this study to evaluate enhanced treatments.
- The study assesses the effectiveness and safety of high-dose rifampicin combined with levofloxacin and the use of corticosteroids for reducing early mortality in HIV-positive patients with disseminated TB.
- A phase III trial design tests these interventions against standard treatments, focusing on all-cause mortality and safety metrics over various timelines.
Mild Behavioral Impairment (MBI) leverages later-life emergent and persistent neuropsychiatric symptoms (NPS) to identify a high-risk group for incident dementia. Phosphorylated tau (p-tau) is a hallmark biological manifestation of Alzheimer disease (AD). We investigated associations between MBI and tau accumulation in early-stage AD cortical regions.
View Article and Find Full Text PDF